Investigational Drug Information for PQR309
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug PQR309?
PQR309 is an investigational drug.
There have been 9 clinical trials for PQR309.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.
The most common disease conditions in clinical trials are Lymphoma, Triple Negative Breast Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are PIQUR Therapeutics AG, University Hospital, Basel, Switzerland, and Churchill Hospital.
There are fifteen US patents protecting this investigational drug and two hundred and thirty international patents.
Summary for PQR309
| US Patents | 15 |
| International Patents | 230 |
| US Patent Applications | 98 |
| WIPO Patent Applications | 109 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 2 (2017-12-01) |
| Vendors | 35 |
Recent Clinical Trials for PQR309
| Title | Sponsor | Phase |
|---|---|---|
| Study of Oral PQR309 in Patients With Advanced Solid Tumors | Case Western Reserve University | Phase 1 |
| Study of Oral PQR309 in Patients With Advanced Solid Tumors | Churchill Hospital | Phase 1 |
| Study of Oral PQR309 in Patients With Advanced Solid Tumors | Hospital Clinic of Barcelona | Phase 1 |
Clinical Trial Summary for PQR309
Top disease conditions for PQR309
Top clinical trial sponsors for PQR309
US Patents for PQR309
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PQR309 | See Plans and Pricing | Manufacturing process for triazine, pyrimidine and pyridine derivatives | UNIVERSITAET BASEL (Basel, CH) PIQUR THERAPEUTICS AG (Basel, CH) | See Plans and Pricing |
| PQR309 | See Plans and Pricing | Uses of indolinone compounds | Oncternal Therapeutics, Inc. (San Diego, CA) | See Plans and Pricing |
| PQR309 | See Plans and Pricing | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (Cambridge, MA) | See Plans and Pricing |
| PQR309 | See Plans and Pricing | Crystalline forms | Array Biopharma Inc. (Boulder, CO) | See Plans and Pricing |
| PQR309 | See Plans and Pricing | Compounds for treating cancer | BICYCLERD LIMITED (Cambridge, GB) | See Plans and Pricing |
| PQR309 | See Plans and Pricing | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIQUR THERAPEUTICS AG (Basel, CH) UNIVERSITAT BASEL (Basel, CH) | See Plans and Pricing |
| PQR309 | See Plans and Pricing | Uses of indolinone compounds | Oncternal Therapeutics, Inc. (San Diego, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PQR309
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PQR309 | Australia | AU2015250994 | 2034-04-22 | See Plans and Pricing |
| PQR309 | Brazil | BR112016023811 | 2034-04-22 | See Plans and Pricing |
| PQR309 | Canada | CA2944697 | 2034-04-22 | See Plans and Pricing |
| PQR309 | China | CN106458968 | 2034-04-22 | See Plans and Pricing |
| PQR309 | European Patent Office | EP3134388 | 2034-04-22 | See Plans and Pricing |
| PQR309 | Spain | ES2713452 | 2034-04-22 | See Plans and Pricing |
| PQR309 | Israel | IL248272 | 2034-04-22 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
